Trending...
- Christy Sports Kicks Off Ski Season with "Ready. Set. Snow!" VIP Nights and Sale Events
- Colorado Families Turn to Private Autopsies for Peace of Mind
- Generation Own: Why Young Americans Are Skipping Corporate Careers to Buy Million-Dollar Businesses
Download
(Photo: Business Wire)
NEW YORK & GREENWOOD VILLAGE, Colo.--(BUSINESS WIRE)--ANANDA Scientific Inc., a research focused bio-pharmaceutical company today announced approval by the US Food and Drug Administration (FDA) of the IND application for a clinical trial evaluating Nantheia™ A1002N5S, an investigational drug using cannabidiol (CBD) in ANANDA's proprietary Liquid Structure™ delivery technology as a potential treatment for Social Anxiety Disorder. The National Center for Complimentary and Integrative Health (HCCIH-a division of the NIH) is providing funding for this trial which will be conducted at the NYU Grossman School of Medicine. (Clinical Trials.gov Identifier: NCT05571592)
More on Colorado Desk
The Principal Investigators for the trial are Naomi Simon, MD, MSc., Professor of Psychiatry and Director of Anxiety, Stress and Prolonged Grief Program at the NYU Grossman School of Medicine and Esther Blessing, MD, PhD, Assistant Professor of Psychiatry at NYU Grossman School of Medicine. This double-blind placebo-controlled trial will study Nantheia™ A1002N5S versus placebo over a 21-day treatment period with the primary outcome measures being the change in Trier Social Stress Test (TSST) induced Anxiety and impact on a neuroimaging biomarker.
"We are delighted to be moving forward with this important study to develop new evidence-based treatments for Social Anxiety Disorder, a distressing and under-addressed condition," said Dr Simon.
Dr. Blessing noted, "It is exciting to be moving forward with clinical trials that build upon promising preclinical results for CBD as a treatment for anxiety disorders."
"We are very pleased to again be working with Dr Simon and Dr Blessing on this important trial that could impact the lives of a large number of people," said Sohail R. Zaidi, ANANDA's CEO. "We look forward to further advancing applications for our investigational drug Nantheia A1002N5S in an indication with a significant unmet medical need."
ABOUT ANANDA SCIENTIFIC
ANANDA is a leading research-focused biopharmaceutical company pioneering high-caliber clinical studies evaluating therapeutic indications such as PTSD, Radiculopathic Pain (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20220308005059%2Fen%2FANANDA-Scientific-and-NYU-Grossman-School-of-Medicine-Announce-First-Patient-Enrolled-in-the-Clinical-Trial-for-Opioid-Sparing-in-Participants-with-Radiculopathic-Pain&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Radiculopathic+Pain&index=8&md5=1583bdfab3e5aa6e72280a53ccffcde5), Anxiety and Opioid Use Disorder (Mt. Sinai (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20211019005004%2Fen%2FANANDA-Scientific%25E2%2580%2599s-Liquid-Structure%25E2%2584%25A2-Cannabidiol-CBD-to-Be-Clinically-Evaluated-for-Opioid-Use-Disorder&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Mt.+Sinai&index=9&md5=c7390692cddb3baae153188a12f6d0d6) and UCLA (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Fananda-scientific-announces-first-patient-enrolled-in-the-clinical-trial-on-the-treatment-of-opioid-use-disorder-oud-301592512.html%3F%3Dprn&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=UCLA&index=10&md5=4423441644a84137a53b0c9ef1100ba5)). The company employs patented delivery technology, (licensed from Lyotropic Delivery Systems (LDS) Ltd (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.lds-biotech.com%2F&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Lyotropic+Delivery+Systems+%28LDS%29+Ltd&index=11&md5=68fda5da92aba5885ea6a7e3c59451c7), in Jerusalem, Israel) to make cannabinoids and plant derived compounds bioavailable, water soluble, and shelf-life stable and focuses on producing effective, premium pharmaceutical products.
More on Colorado Desk
Contacts
ANANDA Scientific Media Relations | Christopher Moore (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fin%2Fchrismoore1%2F&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Christopher+Moore&index=12&md5=86a83b4951580a0d495debb7aa609c7c) | 813 326 4265 | media@anandascientific.com
0) { // Create container for hi-res image jQuery('#bw-release-hires').append('
'); }; }); ]]>
Social Media Profiles
Contacts
ANANDA Scientific Media Relations | Christopher Moore (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fin%2Fchrismoore1%2F&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Christopher+Moore&index=12&md5=86a83b4951580a0d495debb7aa609c7c) | 813 326 4265 | media@anandascientific.com
(Photo: Business Wire)
NEW YORK & GREENWOOD VILLAGE, Colo.--(BUSINESS WIRE)--ANANDA Scientific Inc., a research focused bio-pharmaceutical company today announced approval by the US Food and Drug Administration (FDA) of the IND application for a clinical trial evaluating Nantheia™ A1002N5S, an investigational drug using cannabidiol (CBD) in ANANDA's proprietary Liquid Structure™ delivery technology as a potential treatment for Social Anxiety Disorder. The National Center for Complimentary and Integrative Health (HCCIH-a division of the NIH) is providing funding for this trial which will be conducted at the NYU Grossman School of Medicine. (Clinical Trials.gov Identifier: NCT05571592)
More on Colorado Desk
- Parkchester Oral & Maxillofacial Surgery Celebrates 450+ 5-Star Reviews
- Governor Polis: Colorado's Government is Open and Budget is Balanced
- The AI CEO Partners with D3 Hockey News to Elevate the Voice of Division III Hockey Nationwide
- Statement from the Campaign of Theodis Daniel, Republican for U.S. Congress (TX-18)
- Primos Garage Doors Launches Erie, CO Service Page
The Principal Investigators for the trial are Naomi Simon, MD, MSc., Professor of Psychiatry and Director of Anxiety, Stress and Prolonged Grief Program at the NYU Grossman School of Medicine and Esther Blessing, MD, PhD, Assistant Professor of Psychiatry at NYU Grossman School of Medicine. This double-blind placebo-controlled trial will study Nantheia™ A1002N5S versus placebo over a 21-day treatment period with the primary outcome measures being the change in Trier Social Stress Test (TSST) induced Anxiety and impact on a neuroimaging biomarker.
"We are delighted to be moving forward with this important study to develop new evidence-based treatments for Social Anxiety Disorder, a distressing and under-addressed condition," said Dr Simon.
Dr. Blessing noted, "It is exciting to be moving forward with clinical trials that build upon promising preclinical results for CBD as a treatment for anxiety disorders."
"We are very pleased to again be working with Dr Simon and Dr Blessing on this important trial that could impact the lives of a large number of people," said Sohail R. Zaidi, ANANDA's CEO. "We look forward to further advancing applications for our investigational drug Nantheia A1002N5S in an indication with a significant unmet medical need."
ABOUT ANANDA SCIENTIFIC
ANANDA is a leading research-focused biopharmaceutical company pioneering high-caliber clinical studies evaluating therapeutic indications such as PTSD, Radiculopathic Pain (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20220308005059%2Fen%2FANANDA-Scientific-and-NYU-Grossman-School-of-Medicine-Announce-First-Patient-Enrolled-in-the-Clinical-Trial-for-Opioid-Sparing-in-Participants-with-Radiculopathic-Pain&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Radiculopathic+Pain&index=8&md5=1583bdfab3e5aa6e72280a53ccffcde5), Anxiety and Opioid Use Disorder (Mt. Sinai (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20211019005004%2Fen%2FANANDA-Scientific%25E2%2580%2599s-Liquid-Structure%25E2%2584%25A2-Cannabidiol-CBD-to-Be-Clinically-Evaluated-for-Opioid-Use-Disorder&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Mt.+Sinai&index=9&md5=c7390692cddb3baae153188a12f6d0d6) and UCLA (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Fananda-scientific-announces-first-patient-enrolled-in-the-clinical-trial-on-the-treatment-of-opioid-use-disorder-oud-301592512.html%3F%3Dprn&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=UCLA&index=10&md5=4423441644a84137a53b0c9ef1100ba5)). The company employs patented delivery technology, (licensed from Lyotropic Delivery Systems (LDS) Ltd (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.lds-biotech.com%2F&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Lyotropic+Delivery+Systems+%28LDS%29+Ltd&index=11&md5=68fda5da92aba5885ea6a7e3c59451c7), in Jerusalem, Israel) to make cannabinoids and plant derived compounds bioavailable, water soluble, and shelf-life stable and focuses on producing effective, premium pharmaceutical products.
More on Colorado Desk
- Divine Punk Announces Happy Christmas, a Holiday Soundscape by Rebecca Noelle
- $430 Million 2026 Revenue Forecast; 26% Organic Growth; $500,000 Stock Dividend Highlight a Powerful AI & Digital Transformation Story: IQSTEL $IQST
- Wzzph Deploys 5-Million-TPS Trading Engine with Hot-Cold Wallet Architecture Serving 500,000 Active Users Across Latin America
- Preston Dermatology & Skin Surgery Center and Dr. Sheel Desai Solomon Dominate Raleigh's Best Awards from The News & Observer
- Stone and Leaf Landscaping Launches New Boulder Hardscaping and Fencing Page
Contacts
ANANDA Scientific Media Relations | Christopher Moore (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fin%2Fchrismoore1%2F&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Christopher+Moore&index=12&md5=86a83b4951580a0d495debb7aa609c7c) | 813 326 4265 | media@anandascientific.com
0) { // Create container for hi-res image jQuery('#bw-release-hires').append('
'); }; }); ]]>
Social Media Profiles
- Ananda Scientific (https://www.linkedin.com/company/ananda-scientific)
Contacts
ANANDA Scientific Media Relations | Christopher Moore (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fin%2Fchrismoore1%2F&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Christopher+Moore&index=12&md5=86a83b4951580a0d495debb7aa609c7c) | 813 326 4265 | media@anandascientific.com
Filed Under: Business
0 Comments
Latest on Colorado Desk
- Pastor Darrell Armstrong Suspends Gubernatorial Campaign And Endorses Mikie Sherrill
- Dr. Johnny Shanks Attends Full Arch Growth Conference 2025
- Colorado: Governor Polis Partners with Governors in Urging White House to Stop Disruption to SNAP, Prevent Hunger for Millions of American Families
- Offline Asset Protection: NJTRX Implements 98 Percent Cold Storage as Industry Faces 2 Billion USD Losses
- Thousands of Smiles, Millions of Logo Views: RoarFun Brings Emotions Into Premium Retail Spaces with Formula Simulator for Immersive Brand Activation
- Qvarz LLC Expands Global Reach with High-Precision Quartz Cuvettes and Optical Components
- $300 Million Web3 Initiative and ZIGChain Partnership Power $20 Target in Noble Capital Markets Report for SEGG Media (N A S D A Q: SEGG)
- Stillwater Architects Redefines Luxury Living with Bespoke Remodeling and Renovations in Boulder, CO & Big Sky, MT
- Denver Couples Center Launches New Workshop Series to Help Partners Communicate More Openly About Sex and Intimacy
- Assent Recognizes Manufacturers for Leading Supply Chain Sustainability Programs
- Arc Longevity Sells Out Debut Women's Creatine Gummy
- Colorado First Campaign Launches Mobile Food Banks Across All 64 Counties
- Frost Locker: New Research Reveals Mild Cold—Not Extreme Cold—Delivers Real Health Benefits of Cold Therapy
- Phinge, Home of Netverse, Through its Extensive Software & Hardware Patent Portfolio, Shows Founder & CEO Robert DeMaio's Vision & Innovation
- OddsTrader Reveals Early Favorites and Best Bets to Win March Madness 2026
- Bookmakers Review Releases 2028 Democratic Nominee Betting Odds: Newsom Leads Early Field
- Colorado Springs: Woodland Hills Park celebrates playground improvements with Wednesday ribbon cutting
- Heritage at South Brunswick's Townhome Models Coming Soon!
- PatientNow Acquires Recura, the AI Growth Engine Powering Practice Growth
- Boston Industrial Solutions Unveils New and Improved Natron® UV Screen Printing Ink